Drug development for Alzheimer's disease: recent progress.
Drug development for Alzheimer's disease: recent progress.
复制标题
DOI：
10.5607/en.2010.19.3.120
复制
发表时间：
2010-12
影响因子：
2.4
通讯作者：
Ha I
中科院分区：
文献类型：
--
作者：
Ji W;Ha I
阿尔茨海默病是痴呆症最常见的原因，其特征在于两个主要的病理标志：淀粉样蛋白斑块和神经纤维缠结。基于这两个指标，提出了淀粉样蛋白级联假说，因此，目前大多数治疗方法都集中在从大脑中去除β-淀粉样蛋白肽（Aβ）。此外，已经提出了阻断tau过度磷酸化和聚集的策略，包括开发可以阻断缠结形成的药物。然而，目前市场上没有真正的疾病修饰药物，尽管许多基于Aβ和tau病理学以外的理论的药物正在开发中。本综述的目的是提供关于AD药物的当前发展的信息，并讨论与药物开发相关的问题。
Alzheimer's disease, the most common cause of dementia, is characterized by two major pathological hallmarks: amyloid plaques and neurofibrillary tangles. Based on these two indicators, an amyloid cascade hypothesis was proposed, and accordingly, most current therapeutic approaches are now focused on the removal of β-amyloid peptides (Aβ from the brain. Additionally, strategies for blocking tau hyperphosphorylation and aggregation have been suggested, including the development of drugs that can block the formation of tangles. However, there are no true disease-modifying drugs in the current market, though many drugs based on theories other than Aβ and tau pathology are under development. The purpose of this review was to provide information on the current development of AD drugs and to discuss the issues related to drug development.